SAVING SIGHT: THE MISSION CONTINUES
A NATIONAL EYE
INSTITUTE
BLINDNESS
PREVENTION
INITIATIVE
"We don't need to see patients go blind from diabetic retinopathy anymore. It is time to be hopeful for patients and make sure we're treating them early in the disease course."
Charles Wykoff, MD, PhD
Director of the Retina Consultants of Houston & Steering Committee Member
Everything you need to save your patients' sight. Explore Now.
Resources
PATIENT RESOURCES
- American Diabetes Association (ADA) ▶
- American Optometric Association (AOA): Diabetic Retinopathy ▶
- American Academy of Ophthalmology (AAO): Diabetic Eye Disease ▶
- American Society of Retina Specialists (ASRS): Diabetic Retinopathy ▶
- Centers for Disease Control and Prevention (CDC): Diabetes and Vision Loss ▶
- National Eye Institute (NEI): Diabetic Retinopathy ▶
- Patient education video: Addressing Diabetic Retinopathy: A Way Forward ▶
- Patient education video: Seeing a Way Forward in Diabetic Retinopathy ▶
- Patient education handout: Diabetes & Eye Exams: What You Should Know ▶
- Patient education handout: What You Should Know About Diabetic Retinopathy ▶
DIABETIC RETINOPATHY RESOURCES
- AAO Diabetic Retinopathy Preferred Practice Pattern ® ▶
- Anti-Vascular Endothelial Growth Factor Therapy Can Improve Diabetic Retinopathy Score Without Change in Retinal Perfusion ▶
- ASRS Clinical Practice Guidelines on the Management of Nonproliferative and Proliferative Diabetic Retinopathy Without Diabetic Macular Edema ▶
- Baseline Factors Associated With Diabetic Retinopathy Improvement in RIDE/RISE ▶
- Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy ▶
- PANORAMA: Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy ▶
- Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial ▶
- Protocol S: Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy ▶
- Protocol V Secondary Analysis: Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes with Center-Involved Diabetic Macular Edema and Good Visual Acuity ▶
- Protocol W: Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy ▶
- Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy ▶